Scarica l'app Stockscreener
9.40
4.21%
0.38
Dopo l'orario di chiusura:
9.40
Precedente Chiudi:
$9.02
Aprire:
$9.01
Volume 24 ore:
2.20M
Relative Volume:
1.36
Capitalizzazione di mercato:
$2.95B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-13.81
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
+16.77%
1M Prestazione:
+12.85%
6M Prestazione:
+18.84%
1 anno Prestazione:
+19.59%
Intervallo 1D:
$8.96
$9.41
Intervallo di 1 settimana:
$8.01
$9.41
Portata 52W:
$6.685
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.40 | 2.78B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Here's Why Momentum in Amneal (AMRX) Should Keep going - Yahoo Finance
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - TradingView
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceGuaranteed Profit Setup Watchlist - newsyoung.net
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Brown Rudnick Represented Amneal Pharmaceuticals LLC in $2.1B Term Loan Credit Facility - Brown Rudnick
‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs - insights.citeline.com
Published on: 2025-08-11 02:04:05 - metal.it
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Published on: 2025-08-10 19:02:24 - metal.it
Earnings Beat: Amneal Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - ca.finance.yahoo.com
Amneal 2025 Q2 Earnings Strong Performance as Net Income Surges 112% - AInvest
Amneal (AMRX) Q2 EPS Jumps 56% - AOL.com
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Amneal Pharma Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - The Globe and Mail
Amneal: Q2 Earnings Snapshot - New Haven Register
Amneal Pharmaceuticals Inc (AMRX) Q2 2025 Earnings Call Highlights: Strong Growth and Raised ... By GuruFocus - Investing.com Canada
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights - TipRanks
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
AMNEAL PHARMACEUTICALS Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast - Investing.com
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals shares rise 5.53% intraday after revising earnings guidance and raising fiscal 2025 outlook. - AInvest
Transcript : Amneal Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Knight Therapeutics Submits CREXONT Marketing Authorization Application in Mexico - AInvest
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Surpasses Q2 Earnings ExpectationsNews and Statistics - IndexBox
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025 - MarketScreener
Amneal Pharma A earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Amneal Pharmaceuticals beats Q2 estimates, raises full-year outlook - Investing.com
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q2 2025 Results and Raises Full Year Guidance Following Successful Debt Refinancing - Quiver Quantitative
Amneal Reports Second Quarter 2025 Financial Results - GlobeNewswire
Amneal Pharmaceuticals Set to Announce Earnings Amid Market ChallengesNews and Statistics - IndexBox
Is There Enough Volume to Lift Amneal Pharmaceuticals Inc.Capital Preservation Forecast Insight Strategy - beatles.ru
Amneal Earnings: What To Look For From AMRX - Yahoo Finance
How does Amneal Pharmaceuticals Inc. compare to its industry peersRapid growth opportunities - Jammu Links News
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Consistent triple returns - Jammu Links News
What is Amneal Pharmaceuticals Inc. company’s growth strategyAccelerated profit realization - Jammu Links News
Is Amneal Pharmaceuticals Inc. a good long term investmentFree Wealth Management Insights - Jammu Links News
What analysts say about Amneal Pharmaceuticals Inc. stockStay informed with daily expert analysis - Jammu Links News
How strong is Amneal Pharmaceuticals Inc. company’s balance sheetExceptional profit velocity - Jammu Links News
What makes Amneal Pharmaceuticals Inc. stock price move sharplyTransform your portfolio with high-yield stocks - Jammu Links News
What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Free Investment Community - Jammu Links News
Is Amneal Pharmaceuticals Inc. a growth stock or a value stockTremendous growth opportunities - Jammu Links News
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):